Empirical Asset Management LLC Takes Position in Medpace Holdings, Inc. $MEDP

Posted by Geri Gentry on Aug 19th, 2026

Empirical Asset Management LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,145 shares of the company’s stock, valued at approximately $606,000.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. bought a new stake in Medpace in the second quarter valued at about $1,323,047,000. AQR Capital Management LLC boosted its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the period. Geode Capital Management LLC increased its stake in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Truist Financial raised their price objective on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Barclays set a $600.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $584.18.

View Our Latest Research Report on MEDP

Insider Transactions at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 67,195 shares of company stock valued at $37,989,998. 20.50% of the stock is currently owned by company insiders.

Medpace Stock Down 1.1%

Shares of NASDAQ:MEDP opened at $590.30 on Wednesday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company’s fifty day simple moving average is $541.49 and its 200 day simple moving average is $491.49. The firm has a market cap of $16.48 billion, a price-to-earnings ratio of 34.60, a PEG ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.